HC Bioscience is an innovator and pioneer of protein editing using context agnostic engineered tRNA. Our First in Class approach for protein editing advances beyond genome editing to direct modification of the proteome. A single suppressor tRNA therapy will correct multiple mutant proteins in a variety of disease indications.

Ocular Therapeutix, Inc. is a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye using its proprietary bioresorbable hydrogel-based formulation technology. Ocular Therapeutix’s first commercial drug product, DEXTENZA®, is FDA-approved for the treatment of ocular pain following ophthalmic surgery. OTX-TP (intracanalicular travoprost insert) is an intracanalicular insert in Phase 3 clinical development for the reduction of intraocular pressure in patients with primary open-angle glaucoma and ocular hypertension. The Company’s earlier stage assets include OTX-TIC, an extended-delivery intracameral travoprost implant for the reduction of intraocular pressure in patients with glaucoma and ocular hypertension, as well as sustained release intravitreal implants for the treatment of retinal diseases. These intravitreal implants include OTX-TKI, containing a tyrosine kinase inhibitor (TKI), and, in collaboration with Regeneron, OTX-IVT, an extended-delivery protein-based anti-vascular endothelial growth factor (VEGF) trap. Ocular Therapeutix's first product, ReSure® Sealant, is FDA-approved to seal corneal incisions following cataract surgery.

Clinical-stage, biopharmaceutical and medical device company focused on the development of novel therapeutics for premature infants with respiratory distress syndrome (RDS) and istaroxime, for patients with shock or acute heart failure.

Bench to Bedside

At ImmusanT, we are developing a new class of therapeutic vaccines to change the lives of people living with autoimmune diseases. Our Epitope-Specific Immuno-Therapy™ (ESIT™) platform provides a precision medicine approach to restoring immune tolerance across a range of diseases, including celiac disease and type 1 diabetes. Our lead program, Nexvax2®, is in clinical development with the goal of protecting celiac disease patients against the debilitating effects of gluten. www.ImmusanT.com

Provide value to the College of Pharmacy in developing and achieving its strategic goals and visions through counsel and guidance.

TCN, The Capital Network, is a leading non-profit organization providing extensive educational programs and a community to help early-stage entrepreneurs master the entire funding process and successfully raise seed capital for financing their high-growth startup.

Hepregen Corporation is developing bioengineered solutions for drug development, including a platform for advanced toxicity screening and drug discovery. We are producing a unique, microliver platform that is highly functional and stable. With its high fidelity model of the human liver, Hepregen's bioengineered solution may provide improved predictivity of how drugs will affect the liver once in humans. As a unique liver model system, it has wide applications as a decision-making and enabling platform in the drug development pipeline for the pharmaceutical and biotechnology sectors

Specialty pharmaceutical company developing a proprietary pulmonary drug delivery and formulations that allow for delivery of drugs more efficiently to and through the lungs.

Specialty pharmaceutical company that developed an inhaled pulmonary vasodilator (INOmax)that selectively dilates the pulmonary vasculature and improves ventilation and perfusion (V/Q) mismatch. Initial indication: PPHN. Nobel Prize Medicine 1998: discovery that nitric oxide is a signaling molecule in the cardiovascular system.

Devices/catheters